Reduced Mortality With Sodium-Glucose Cotransporter–2 Inhibitors in Observational Studies
Author:
Affiliation:
1. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada (S.S.)
2. Department of Epidemiology and Biostatistics, Department of Medicine, McGill University, Montreal, Canada (S.S.)
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference6 articles.
1. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
2. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
3. Immortal Time Bias in Pharmacoepidemiology
4. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores
5. Metformin and the Risk of Cancer
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment with sodium‐glucose cotransporter 2 inhibitors and risk of lower‐limb amputations;Diabetes, Obesity and Metabolism;2024-07-11
2. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-world Evidence Studies on Treatment Effects (Japanese Version)： A Good Practices Report of a Joint ISPE/ISPOR Task Force;Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku;2023-06-30
3. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan;Diabetes mellitus;2023-05-15
4. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses;JAMA;2023-04-25
5. Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study;Journal of Diabetes Investigation;2023-01-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3